Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/30/2024 | $19.00 | Buy | Guggenheim |
| 6/17/2022 | $7.00 | Outperform | BMO Capital Markets |
| 6/9/2022 | Outperform → Mkt Perform | William Blair | |
| 9/10/2021 | $23.00 → $26.00 | Buy | Stifel |
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will participate in the following upcoming investor conferences. JonesTrading Virtual Genetic Medicine Day Date: Monday, November 25, 2024 Time: 11:00 AM ET Panel Title: Next Generation of Gene Editing; Going Beyond "Cas" Webcast Link: Register Here AussieMit Date: Friday, November 29, 2024 Time: 2:50 PM AEDT Presentation Title: Emerging Therapies A live webcast for the JonesTrading Virtual Genetic Medicine Day will also be accessible on Precision's website in the
– PBGENE-HBV preclinical data reinforce safety profile and potential to deliver a functional cure for chronic hepatitis B, supporting advancement into first-in-human clinical study – – Phase 1 dose escalation and expansion trial, ELIMINATE-B, designed to assess safety and efficacy measured by durable reduction of key viral biomarkers – – Global study recruiting patients following clearance of first clinical trial application (CTA), with additional CTAs pending approval; U.S. investigational new drug (IND) anticipated in 2025 – – Investor event today, November 15, 10:00 a.m. EST / 7:00 a.m. PST, to feature presentations from company management and key opinion leader perspectives on PBG
- Received approval for first Clinical Trial Application to advance PBGENE-HBV into first-in-human trials for treatment of chronic hepatitis B; additional global regulatory applications pending approval - Opened PBGENE-HBV phase 1 clinical program in Moldova; patient screening underway with clinical data expected in 2025 - Strengthened infectious disease capabilities with key clinical talent added to senior leadership team - Expected cash runway into the second half of 2026 with sufficient capital to phase 1 clinical data for multiple in vivo gene editing programs - Company to host virtual investor event highlighting final PBGENE-HBV preclinical safety data and Phase 1 trial plans on No
Guggenheim initiated coverage of Precision BioSciences with a rating of Buy and set a new price target of $19.00
BMO Capital Markets initiated coverage of Precision BioSciences with a rating of Outperform and set a new price target of $7.00
William Blair downgraded Precision BioSciences from Outperform to Mkt Perform
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, is presenting data today at the United Mitochondrial Disease Foundation's (UMDF) Mitochondrial Medicine 2024 Conference being held in Cleveland, Ohio from June 26-29, 2024.
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that the company will present preclinical data for its PBGENE-HBV clinical candidate at the European Association for the Study of the Liver Congress (EASL), highlighting the differentiated ability of ARCUS to make efficient, durable, and targeted elimination edits. The poster presentation highlights data in primary human hepatocytes demonstrating the high specificity and lack of detectable off-target editing for PBGENE-HBV at therapeutically relevant doses. The poster will also showcase non-human primate data de
HC Wainwright & Co. analyst Patrick Trucchio reiterates Precision BioSciences (NASDAQ:DTIL) with a Buy and maintains $60 price target.
SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)
SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)
SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will publish financial results for the third quarter 2024 and provide a business update on November 4, 2024. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enab
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that it will publish financial results for the second quarter 2024 and provide a business update on August 1, 2024. About Precision BioSciences, Inc. Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more inten
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will publish financial results for the first quarter 2024 and provide a business update on Monday, May 13, 2024. About Precision BioSciences, Inc. Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabili
10-Q - PRECISION BIOSCIENCES INC (0001357874) (Filer)
8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)
8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)
- Wholly owned programs PBGENE-HBV for Chronic Hepatitis B virus and PBGENE-PMM for m.3243 mitochondrial disease on track for IND and/or CTA submissions in 2024 and 2025, respectively - Expanded Hepatitis Scientific Advisory Board with addition of world-class clinical investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., M.P.H. - Sufficient capital to realize Phase 1 clinical data for multiple in vivo gene editing programs; Expected cash runway into the second half of 2026 - Regained control of three advanced preclinical programs for development internally or with partners, including a novel gene editing approach for Duchenne Muscular Dystrophy Precision BioSciences, Inc. (NASDA
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced the appointment of Mark Sulkowski, M.D. and Jordan Feld, M.D., M.P.H. to its Hepatitis Scientific Advisory Board (SAB). Dr. Sulkowski and Dr. Feld will join Raymond Schinazi, Ph.D., DSc, inaugural member of Precision's Hepatitis SAB, to provide counsel and deepen the Company's scientific and clinical expertise ahead of Precision's anticipated Investigational New Drug (IND) and/or Clinical Trial Application (CTA) submission of PBGE
New Director Brings Proven Financial and Leadership Experience Fifth Director Added to the Board of Directors Since April 2021 Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Melinda Brown has been appointed as a Director on the Company's Board of Directors and Chair of the Board's Audit Committee. Ms. Brown is a financial expert with proven experience leading accounting, finance and enterprise risk management teams in large, public companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202